The rationale for the study rested on a well-established body of cell biology. G protein-coupled receptors such as the alpha-1A-adrenoceptor, which drives prostate smooth muscle contraction, do not simply sit at the cell surface. After agonist stimulation they are internalized into endosomal vesicles, and their subsequent fate, whether recycling back to the membrane or degradation in lysosomes, is governed by Rab GTPases. In cell culture systems with stable overexpression of alpha-1A-adrenoceptors, internalized receptors interact with Rab7, which typically directs them toward late endosomes and eventual degradation. Meanwhile, Rab27 is known to regulate exocytosis, including the release of neurotransmitters from synaptic vesicles, a process central to the neurogenic contractions that noradrenaline elicits in prostate smooth muscle. If Rab7-mediated degradation limited receptor availability, or if Rab27-dependent exocytosis limited transmitter release, blocking these GTPases might plausibly amplify or dampen prostate contractions.

To test this, the team examined tissue strips from two clinically distinct cohorts. The first came from patients undergoing holmium or thulium laser enucleation of the prostate for advanced, medication-refractory benign prostatic hyperplasia, a group characterized by severe symptoms, high postvoid residual urine volumes, prostate volumes around 90 to 95 milliliters and a mean age of 71 years. The second came from men undergoing radical prostatectomy for prostate cancer who had never had surgery for benign prostatic hyperplasia and who generally showed only mild or moderate symptoms, with a mean age of 66 years and prostate volumes of roughly 49 to 56 milliliters. Tissue samples were mounted in myograph chambers within three hours of surgery, equilibrated, and contracted with potassium chloride as a reference stimulus to normalize for differences in strip size and smooth muscle content.

The experimental design was deliberately paired and rigorous. In each experiment, tissue strips from a single prostate were split between inhibitor-treated and vehicle-treated chambers, allowing direct comparison within the same patient and accounting for the considerable histological heterogeneity of benign prostatic hyperplasia, which ranges from stromal to glandular phenotypes with varying fibrosis. After a 30-minute preincubation, concentration response curves were generated for three different alpha-1-selective agonists, phenylephrine, methoxamine and noradrenaline, and frequency response curves were recorded under electric field stimulation, which activates the tissue’s own nerves and mimics neurogenic contraction. The inhibitors used were CID1067700, reported to inhibit Rab7 with a nanomolar affinity, and nexinhib20, developed as an inhibitor of Rab27a-mediated exocytosis, each tested at 1 and 10 micromolar.

The results were strikingly uneventful for CID1067700. In laser-enucleated tissues, neither 1 nor 10 micromolar of the compound produced consistent changes in contractions induced by any of the three agonists or by electric field stimulation. Isolated statistically significant differences appeared, such as a decrease in noradrenaline responses at the lower concentration and an increase in phenylephrine responses at the higher one, but these were never paralleled by consistent changes in area under the curve or maximal contraction, and the other agonists were unaffected. The same pattern held in prostatectomy specimens without prior surgery for benign prostatic hyperplasia. Half-maximal effective concentrations and frequencies were unchanged throughout, indicating that neither the sensitivity nor the maximal capacity of the adrenergic contractile machinery was reproducibly altered.

Nexinhib20 produced similarly null results for agonist-induced contractions in both tissue types, with scattered, agonist-specific and directionally inconsistent changes that the authors attribute to experimental variability in heterogeneous human tissue. The one exception was a reduction of electric field stimulation-induced contractions by 10 micromolar nexinhib20 in laser-enucleated tissues, where the maximal neurogenic contraction fell from 79 percent to 40 percent of the potassium chloride reference response. Because agonist-induced contractions were simultaneously unaffected, this pattern would fit a presynaptic effect on neurotransmitter release, an exocytotic process plausibly involving Rab27, rather than altered postsynaptic adrenoceptor signaling. The authors urge caution, however, noting that the effect was absent in prostatectomy tissues and may reflect variability or chance, and they call for further work to clarify differences in neurogenic responses between the two tissue sources.

Why did a compound with a reported nanomolar affinity for Rab7 fail to touch adrenergic contractions in intact human tissue? The study’s discussion offers a sobering audit of the pharmacological tools themselves. CID1067700 was the first compound with proven inhibition of a Rab GTPase, but follow-up work showed it inhibits BODIPY-GTP binding to Rab7, H-Ras, Cdc42, RhoA and Rac1 with similar nanomolar potencies, making it effectively a pan-GTPase inhibitor in fluorescence-based assays. Critically, RhoA is essential for smooth muscle contraction, and Rac1 and Cdc42 also contribute to prostate smooth muscle tone, so off-target inhibition of these proteins should have reduced contractions, yet nothing of the sort was observed. The authors argue that results from BODIPY-GTP assays may be confounded by allosteric artifacts, and note that in pulldown assays measuring active Rab7, effective concentrations of CID1067700 climb to 40 to 120 micromolar, far above the range tested here. Reported effective concentrations of the compound across different models span from 20 nanomolar to 40 micromolar, an inconsistency that itself questions assay validity.

Nexinhib20’s profile is similarly complicated. Developed to block Rab27a-JFC1-mediated exocytosis of neutrophil granules with an IC50 of 330 nanomolar, it also inhibits Rac1 activation in pulldown assays with an IC50 around 29 micromolar, and its maximum inhibition of the Rab27-effector interaction appears capped at roughly 50 percent. The concentrations used in the prostate study should have produced at least partial inhibition of the intended targets and known off-targets, yet agonist-induced contractions remained intact. Taken together, the findings suggest that posttranslational regulation of endogenous alpha-1-adrenoceptors in the human prostate does not reproducibly depend on pathways sensitive to these two inhibitors, and that this holds across different clinical stages of benign prostatic hyperplasia.

The authors draw a broader conclusion that resonates well beyond urology. Regulatory mechanisms identified in cell culture with receptor overexpression, and affinities measured in biochemical or fluorescence-based assays with recombinant proteins, may simply not transfer to endogenous receptor function in intact human tissue. Previous work had shown Rab7-dependent trafficking of overexpressed alpha-1A-adrenoceptors, and ligand-specific differences in Rab interactions, with noradrenaline and methoxamine directing receptors toward Rab7-mediated degradation while oxymetazoline favored Rab9-associated slow recycling. None of this translated into functional dependence on Rab7 in real prostate strips. Other Rab isoforms, including Rab1, Rab5 and Rab9, remain candidate regulators, but suitable pharmacological tools are scarce, and the field lacks reliable inhibitors for most posttranslational regulators of adrenoceptors.

There may also be unexplored therapeutic angles. Rab7 and Rab27 have been implicated in cellular senescence, chronic inflammation and fibrosis in other tissues, processes increasingly recognized as drivers of medication-refractory benign prostatic hyperplasia, where structural changes rather than smooth muscle tone alone may limit drug response. Whether CID1067700 or nexinhib20 could modulate such processes in the prostate remains unknown. For now, the study’s most valuable contribution is methodological honesty: a carefully controlled, paired examination of living human tissue showing that elegant mechanisms demonstrated in overexpression systems can vanish when confronted with the messy reality of endogenous receptors, heterogeneous patient tissue and physiologically relevant contractile function. Resistance of prostatic alpha-1-adrenoceptors to Rab-mediated degradation, the authors speculate, might even help preserve receptor function and sustain smooth muscle tone in obstruction, a possibility that future studies with better tools will need to address.

Subject of Research: Effects of Rab GTPase inhibitors on adrenergic contraction of human prostate smooth muscle

Article Title: Adrenergic Contraction of Human Prostate Tissues Is Maintained Under the Rab GTPase Inhibitors Nexhinib20 and CID1067700

Article References: Troffer, L., Cen, P., Brandstetter, M., Xu, Y., Keller, P., Stadelmeier, L., Weinhold, P., Tamalunas, A., Stief, C. G., & Hennenberg, M. (2026). Adrenergic Contraction of Human Prostate Tissues Is Maintained Under the Rab GTPase Inhibitors Nexhinib20 and CID1067700. Pharmacology Research & Perspectives, 14(6), Article e70331. https://doi.org/10.1002/prp2.70331

Image Credits: AI Generated

DOI: 10.1002/prp2.70331

Keywords: benign prostatic hyperplasia, alpha-1-adrenoceptors, Rab GTPases, smooth muscle contraction, prostate, organ bath, CID1067700, nexinhib20, receptor trafficking, neurogenic contraction, pharmacology, G protein-coupled receptors

A team of French researchers has now built exactly that tool. Writing in PLOS Computational Biology, Chloé Weckel of the French National Research Institute for Agriculture, Food and the Environment and her colleagues, together with collaborators including Stefan Haar of the École Polytechnique and Romain Yvinec of INRAE, present a generic dynamic model of GPCR signaling that explicitly incorporates receptor trafficking: internalization from the plasma membrane, sorting inside endosomes, and recycling back to the surface. The work, published on September 29, 2026, is not merely another computational exercise. It is an attempt to make the spatial choreography of receptors a first-class citizen in theoretical models, rather than an afterthought, and then to test what that choreography actually contributes to a real hormonal response.

The central premise of the study is deceptively simple. If the kinetics and spatial localization of signaling determine how a cell responds to a ligand, then any model that ignores where the receptor is at a given moment is missing a critical variable. Receptors do not sit still. Ligand binding can trigger their internalization into endosomes, where they may continue to activate G proteins and other effectors, or they may be sorted for destruction. Many receptors are recycled back to the cell surface, replenishing the pool available for the next round of stimulation. Each of these steps has its own timescale, and each timescale feeds back into the shape of the signaling curve, how fast the response rises, how long it persists, and whether it is sustained or transient. The new model captures this interplay directly, allowing researchers to systematically characterize how endosomal dynamics and receptor recycling influence ligand-induced cellular responses.

What makes the approach powerful is its generality. Rather than hard-coding the behavior of one receptor, the authors constructed a framework in which trafficking and signaling compartmentalization are explicit, modular components. This means the same architecture can be adapted to different GPCRs by adjusting parameters, and, crucially, it means the model can be interrogated: which trafficking steps matter most for a given ligand, and under what conditions does endosomal signaling dominate over surface signaling? Such questions have real pharmacological weight. Two drugs that activate the same receptor with similar potency in a standard surface-based assay could produce very different cellular outcomes if one of them preferentially drives internalization or blocks recycling. A model that can distinguish these scenarios offers a far more refined instrument for characterizing ligands than conventional dose-response curves.

To prove the point, the team turned to a receptor with major biological and agricultural significance: the follicle-stimulating hormone receptor, or FSHR. FSH is the master regulator of reproductive function, driving follicle growth in the ovary and sperm production in the testis, and its receptor is a canonical GPCR whose signaling has been studied intensively. The researchers paired their model with high-throughput kinetic data on FSH-induced signaling, using a model selection strategy to determine which combinations of trafficking and signaling assumptions best explained the observed dynamics. This is where the study delivers its most striking surprise: although only a small fraction of FSH receptors is actually internalized, those few endosomal receptors generate a highly active signaling response inside the cell.

The implication of that finding is outsized. If a minority of internalized receptors can punch far above their numerical weight, then any drug or genetic perturbation that alters receptor trafficking, even modestly, could have dramatic consequences for the overall signaling output. A compound that speeds up internalization, slows recycling, or changes how receptors are sorted within endosomes would not merely shuffle receptors around; it would reshape the very profile of the cellular response. For reproductive medicine and livestock breeding, where FSHR ligands are used or studied therapeutically, this reframes how such molecules should be evaluated. A ligand’s pharmacological identity cannot be fully captured without knowing what it does to receptor traffic.

The study also speaks to a broader conceptual shift in cell biology. The emerging view of signaling holds that location is information: a receptor signaling from an endosome encounters a different set of effector molecules, scaffold proteins, and deactivating enzymes than it does at the plasma membrane, so the same receptor can produce qualitatively different downstream effects depending on where it is active. Endosomal signaling has been implicated in sustained responses such as the prolonged activity of certain receptors involved in neuronal function and metabolism. By building trafficking into a quantitative framework, the French team has provided a way to move this discussion from anecdote to arithmetic, converting a qualitative appreciation of spatial organization into testable, parameterized predictions.

Methodologically, the work sits at the intersection of dynamical systems modeling and high-throughput experimental biology. The model selection approach, in which competing mechanistic hypotheses are scored against kinetic data, allows the data themselves to adjudicate which trafficking behaviors are essential and which are dispensable for explaining the observed signaling. This discipline matters because GPCR systems are notoriously over-parameterized: with dozens of rate constants describing binding, internalization, degradation, recycling, and signaling at multiple locations, a model can easily become flexible enough to fit anything. By forcing the model to compete against real FSHR kinetics, the researchers ensured that the retained mechanisms, including the outsized contribution of endosomal signaling, earned their place in the explanation rather than being assumed from the outset.

The authors are careful to frame their contribution as generalizable. Beyond FSHR, the methodology offers a strategy for modeling trafficking dynamics across the GPCR superfamily, which includes receptors for neurotransmitters, hormones, sensory stimuli, and countless other ligands. Because the framework treats internalization, endosomal sorting, and recycling as explicit, tunable processes, it can in principle be calibrated to any receptor for which suitable kinetic data exist. That opens the door to a systematic, comparative pharmacology of trafficking: a future in which every ligand is characterized not only by how strongly it activates a receptor but by how it redistributes that receptor across the cell’s interior landscape.

For drug developers, the message is both a warning and an opportunity. The warning is that assays confined to the cell surface may systematically misjudge compounds whose most important effects occur inside endosomes, or whose toxicity and efficacy hinge on perturbing receptor recycling. The opportunity is that trafficking itself becomes a design target: molecules could be engineered to prolong or curtail endosomal signaling deliberately, tailoring not just the strength of a drug’s effect but its duration and spatial character. As the PLOS Computational Biology study makes clear, the journey of a receptor into the cell is not the end of its story. In many cases, it is where the real signaling begins, and understanding that journey quantitatively may prove as important to future pharmacology as the receptor itself.

Subject of Research: Spatiotemporal computational modeling of GPCR signaling, endosomal dynamics, and receptor recycling

Article Title: Spatiotemporal modeling of GPCR signaling: The role of endosomal dynamics and receptor recycling

Article References: Weckel, C., Gourdon, J., Darrigade, L., Jugnarain, V., Crépieux, P., Reiter, E., Jean-Alphonse, F., Haar, S., & Yvinec, R. (2026). Spatiotemporal modeling of GPCR signaling: The role of endosomal dynamics and receptor recycling. PLOS Computational Biology, 22(9), e1014790. https://doi.org/10.1371/journal.pcbi.1014790

Image Credits: AI Generated

DOI: 10.1371/journal.pcbi.1014790

Keywords: GPCR signaling, endosomes, receptor recycling, receptor trafficking, FSHR, computational biology, model selection, pharmacology, cell signaling, ligand characterization, PLOS Computational Biology, spatiotemporal modeling

The insulin receptor is a receptor tyrosine kinase, but it breaks the rules that govern many of its relatives. Rather than dimerizing upon ligand binding, IR exists as a preformed dimer at the cell surface, held in an autoinhibited conformation in which the ectodomain geometry keeps the intracellular kinase domains separated and poorly oriented for the trans-phosphorylation that ignites signaling. Insulin activates the receptor through a multistep trajectory involving two binding sites: site 1, formed by the leucine-rich repeat domain L1 of one protomer together with the alpha-chain C-terminal segment of the opposing protomer, and site 2, located on the lateral surface of the first fibronectin type III domain. When the receptor is fully liganded, up to four insulin molecules can engage it, stabilizing a T-shaped conformation that brings the kinase domains into productive proximity.

Once activated, the receptor autophosphorylates across its activation loop, juxtamembrane region, and C-terminal tail, creating a docking platform for adaptor proteins. The classical branches follow: insulin receptor substrate proteins recruit PI3K to drive the AKT pathway and metabolic regulation, while the adaptor Shc channels signaling into the MAPK cascade, more closely tied to mitogenic and proliferative outputs. Crucially, these are not simply parallel wires but competing engagement routes, and their relative utilization shapes the overall signaling balance. That balance, the review emphasizes, can be distorted in disease, most famously in selective insulin resistance, where the metabolic AKT arm fails while the mitogenic MAPK arm persists, a combination implicated in endothelial dysfunction and in the uncoupling of hepatic glucose production from lipogenesis in type 2 diabetes.

Beyond pathway choice, the review highlights two underappreciated dimensions of IR regulation: trafficking and spatial organization. Internalized receptors were long thought to be simply silenced and recycled, but accumulating evidence shows that endosomal IR can remain signaling-competent, and that insulin-stimulated AKT2 phosphorylation depends on specific endosomal compartments enriched in the protein WDFY2. Genetic mouse models drive the point home. Disrupting the interaction between IR and the spindle checkpoint protein MAD2 delays receptor endocytosis, reduces insulin clearance, elevates circulating insulin, and reshapes both membrane and intracellular signaling, with measurable consequences for lipid metabolism. Conversely, hepatic overexpression of EphB4 drives receptor degradation and insulin resistance, while loss of the beta-cell scavenger inceptor improves glucose tolerance. Precise control of receptor traffic, these studies show, is required for systemic metabolic homeostasis.

Super-resolution imaging adds yet another layer: IR dimers are organized into nanoclusters roughly 74 nanometers across, and insulin stimulation modestly enlarges these assemblies without fundamentally reorganizing them. To test whether ligand architecture matters, researchers built a DNA origami platform presenting insulin at defined valency and spacing. Multivalent insulin NanoRods bound the receptor more tightly, dissociated more slowly, and induced stronger autophosphorylation and downstream transcriptional responses than monovalent insulin. Receptor activation, in other words, is sensitive to nanoscale geometry, not merely to ligand identity, and even the temporal pattern of insulin exposure matters: pulsatile delivery elicits stronger hepatic signaling than constant infusion at an equivalent dose.

The most striking section of the review concerns engineered insulin mimetics, which the authors treat not as insulin substitutes but as molecular probes exposing signaling states inaccessible to the native hormone. Phage display screens originally identified the site 1 and site 2 hotspots, and fusing peptides targeting them in different orientations produced either agonists or antagonists. The 31-amino-acid peptide S597 activates the receptor through a non-native geometry, cross-linking site 1 and site 2 across protomers, and preferentially stimulates metabolic over mitogenic signaling, with in vivo data suggesting possible benefits in atherosclerosis. Reversing the fusion orientation yields antagonists such as S961, which cryo-electron microscopy reveals trap the receptor in an intermediate conformation between the inactive and active states. Fusion geometry, not binding affinity, determines whether a synthetic ligand stabilizes an active, biased, or antagonistic configuration.

Computational protein design has now made that principle fully explicit. De novo designed binders, roughly 7 kilodaltons each and directed against individual extracellular domains, were fused in defined orientations with tunable linker flexibility. Reversing the topology flipped the function: site 2 to site 1 constructs act as agonists, while site 1 to site 2 constructs act as antagonists. Linker rigidity further tunes the output. Rigid constructs such as RF-405 stabilize a compact, fully active conformation and signal in a balanced, insulin-like fashion, whereas flexible constructs such as S2-F1-S1 produce partial autophosphorylation, attenuated mitogenic signaling, and altered trafficking. In animals, these designer agonists lower glucose with slower onset but longer duration than insulin, bypass certain disease-causing IR mutations, and show reduced stimulation of cancer cell proliferation compared with the native hormone.

Aptamers and antibodies round out the modulator toolkit. The DNA aptamer IR-A43 does not activate the receptor alone but potentiates insulin signaling by stabilizing an asymmetric, singly occupied conformation, while IR-A62 behaves as a concentration-dependent allosteric modulator that can lower glucose even under insulin-deficient conditions. Monoclonal antibodies such as 83-7 and 83-14, and the engineered XMet series, demonstrate that epitope selection can tune the receptor from activation to inhibition: XMetA acts as a partial agonist with preferential AKT signaling, XMetS potentiates insulin action, and XMetD reverses hypoglycemia in hyperinsulinemic mouse models. Together these ligands show that IR activation can be synthetically programmed.

The disease implications are broad. In cancer, hyperinsulinemia is associated with increased risk and progression, tumors preferentially express the IR-A isoform that binds IGF2 and sustains mitogenic signaling, and the super-mitogenic analog Asp(B10), which induced mammary tumors in rodents, stands as a cautionary example of what mitogenic bias can do. In polycystic ovary syndrome, skeletal muscle shows post-receptor defects centered on the IRS-PI3K-AKT axis, while ovarian adaptor remodeling promotes androgen excess. In Alzheimer disease, postmortem tissue reveals brain insulin resistance with preserved signaling proteins but elevated inhibitory IRS1 serine phosphorylation, and the genetic risk factor APOE4 impairs neuronal signaling by trapping the receptor in endosomes. Severe insulin resistance syndromes caused by germline IR mutations, meanwhile, may one day be treated with mimetics that activate the receptor through mechanisms distinct from insulin.

The authors are candid about the challenges ahead: it remains unclear which signaling biases are beneficial versus pathological, how bias is maintained in complex physiological environments, and how trafficking, ligand geometry, and adaptor selection integrate in vivo. Translational hurdles, from peptide stability to CNS delivery, are substantial, though the engineering playbook proven by GLP-1 receptor agonists offers a template. Still, the conceptual shift is hard to miss. If insulin action is a programmable network rather than a simple switch, then the future of therapy may lie not in replacing insulin but in reprogramming its receptor, selectively and precisely, in the tissues and disease contexts where it matters most.

Subject of Research: Non-canonical insulin receptor signaling and the design of insulin mimetics

Article Title: Insulin mimetics and non-canonical insulin receptor signaling: mechanisms and disease relevance

Article References: Park, J., & Choi, E. (2026). Insulin mimetics and non-canonical insulin receptor signaling: mechanisms and disease relevance. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01862-5

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01862-5

Keywords: insulin receptor, insulin mimetics, biased agonism, receptor trafficking, endosomal signaling, protein design, type 2 diabetes, insulin resistance, cancer, PCOS, Alzheimer disease, receptor tyrosine kinase

The μ-opioid receptor, or MOR, is the primary molecular target for most clinically used analgesic opioids, from morphine to fentanyl. Decades of research have focused on what happens at the plasma membrane, where activated receptors are phosphorylated, bind β-arrestin, and are pulled into the cell by endocytosis. Chronic exposure to certain agonists reduces the number of receptors displayed on the cell surface, a process widely believed to contribute to tolerance and dependence. But the new work shifts attention to a much earlier stage of the receptor’s life: its maturation and export from the endoplasmic reticulum, the cellular factory where membrane proteins are synthesized and folded.

Studying this early phase in normal receptors is difficult because MORs traffic efficiently to the plasma membrane, leaving almost nothing in the endoplasmic reticulum to observe. To overcome this obstacle, the research team, led by Matthew J. Mulcahy, Stephen N. Grant, and Henry A. Lester, used a rare mutant called MOR[N190K], which is substantially retained in the endoplasmic reticulum. When cells expressing this mutant were treated with the antagonists naltrexone or naloxone, fluorescently tagged receptors suddenly appeared outlining the cell surface, reaching a distribution resembling that of the wild-type receptor. The drugs, in other words, had rescued the mutant receptor’s journey to the membrane.

The mechanism behind this rescue appears to involve endoplasmic reticulum exit sites, or ERES, specialized regions of the organelle where newly folded cargo is packaged into coat protein vesicles for transport to the Golgi apparatus. To visualize these structures, the researchers used a fluorescently tagged version of Sec24D, a core component of the ERES machinery. First, they needed to confirm that the receptor and Sec24D actually interact. Using sensitized emission Förster resonance energy transfer, a live-cell technique that detects when two fluorescently labeled proteins come within a few nanometers of each other, they showed that MOR[N190K] sits in close proximity to Sec24D inside the endoplasmic reticulum. A control experiment with Rab5, a marker of early endosomes, produced no comparable signal, ruling out the possibility that the interaction was happening after the receptor had already reached the cell surface and been internalized.

With that interaction established, the team turned to three-dimensional confocal microscopy to ask what happens to ERES when cells are flooded with opioid drugs. They measured the fraction of the cytoplasmic volume occupied by ERES, a metric chosen because, as earlier work by Heinzer and colleagues reasoned, expanding the size of exit sites is a more effective way to boost secretory flux than simply adding more of them. After twelve hours of treatment with ten micromolar concentrations of drug, four ligands stood out: naltrexone, naloxone, morphine, and fentanyl all significantly increased the ERES fraction. Buprenorphine, methadone, and two positive allosteric modulators, BMS 986122 and BMS 986124, did not.

The pattern held up under several additional tests. N-methyl-naltrexone, a permanently charged derivative of naltrexone that crosses the plasma membrane far less readily, produced only a modest shift in ERES levels, consistent with the idea that the drug must physically enter the cell and reach the endoplasmic reticulum to chaperone the receptor. A shorter four-hour incubation with naltrexone yielded only a partial increase, suggesting that the process builds over time as receptors cycle through the secretory pathway. And when the researchers blocked COPI-dependent retrograde transport with brefeldin A, naltrexone and naloxone lost their ability to raise ERES levels entirely. That last result implies that the mutant receptor must make multiple round trips between the endoplasmic reticulum and the Golgi before it is fully matured and ready for the plasma membrane, a requirement that mirrors findings from pharmacological chaperoning studies of other receptor families.

Perhaps the most intriguing result came from a double mutant. Serine 375, a residue in the receptor’s C-terminal tail, is a well-known phosphorylation site that governs arrestin recruitment and receptor internalization at the cell surface. When the researchers mutated this serine to alanine in the ER-retained background, creating MOR[N190K][S375A], naltrexone still chaperoned the receptor effectively, but morphine and fentanyl lost their chaperoning power altogether. This suggests that the agonists’ ability to promote receptor export depends on S375, possibly because they can induce phosphorylation of the residue even while the receptor is still maturing inside the endoplasmic reticulum. It also reveals an unexpected, “inside-out” role for a residue that has almost exclusively been studied in the context of events at the plasma membrane.

The team also tested and rejected an alternative explanation for the upregulation. One hypothesis held that antagonists raise intracellular cyclic AMP levels, which in other cell types has been shown to coincide with a global increase in protein trafficking. Because MOR activation suppresses cAMP, blocking basal receptor activity with an antagonist could plausibly raise cAMP and thereby accelerate trafficking generally. But a competitive ELISA assay on cell lysates showed no significant cAMP increase after twelve hours of naltrexone treatment, while the positive control, forskolin, produced the expected rise. With the cAMP pathway ruled out, the pharmacological chaperoning hypothesis stands as the leading explanation for how these ligands expand ERES levels and push the mutant receptor toward the cell surface.

The clinical stakes of this basic cell biology are considerable. Naltrexone and naloxone are the two most commonly prescribed opioid antagonists, given to people recovering from opioid use disorder. Chronic antagonist treatment is known to increase the number of opioid receptors on the cell surface, producing a supersensitivity that can persist for weeks after the final dose. If a patient relapses during that window, the expanded receptor population raises the risk of a fatal overdose. Understanding that antagonists may drive this upregulation, at least in part, by chaperoning receptors through the early secretory pathway opens a potential strategy for decoupling the therapeutic benefits of antagonist therapy from its most dangerous side effect.

The authors are careful about the limits of their findings. In pilot experiments, neither naltrexone nor the other ligands increased ERES levels or surface expression of the wild-type receptor, so the chaperoning mechanism demonstrated here applies only to the rare MOR[N190K] mutant, and the microscopy approach cannot yet be applied to native neurons in intact neural circuits. Generalizing the mechanism to explain supersensitivity in animals with normal receptors will require additional, still unknown elements of the chaperoning process, much as the mechanisms behind nicotine’s selective upregulation of nicotinic receptors in certain cell types remain only partly resolved. Interestingly, buprenorphine’s known ability to rescue the mutant receptor’s surface expression despite failing to raise ERES levels suggests that it acts through a different, ERES-independent trafficking step, hinting that multiple routes to the plasma membrane can be targeted by small molecules.

Even with those caveats, the study makes a strong case that pharmacological chaperoning deserves a place in any complete account of a drug’s efficacy profile. Ligands long classified purely by their actions at the cell surface, agonists and antagonists alike, turn out to influence the internal processing of their own receptors, changing how cells respond to drug exposure from the inside out. As the authors note, this principle now appears to span several drugs of abuse, from nicotine to opioids, and the hope is that future experiments will keep following opioid receptors into the endoplasmic reticulum and Golgi, far from the plasma membrane where most of their story has been told until now.

Subject of Research: Pharmacological chaperoning of the μ-opioid receptor by opioid agonists and antagonists via endoplasmic reticulum exit sites

Article Title: Naltrexone, Naloxone, Morphine, and Fentanyl Pharmacologically Chaperone a Mutant μ‐Opioid Receptor via an Endoplasmic Reticulum Exit Site‐Dependent Pathway

Article References: Grant, S. N., Mulcahy, M. J., & Lester, H. A. (2026). Naltrexone, Naloxone, Morphine, and Fentanyl Pharmacologically Chaperone a Mutant μ‐Opioid Receptor via an Endoplasmic Reticulum Exit Site‐Dependent Pathway. Pharmacology Research & Perspectives, 14(5), Article e70315. https://doi.org/10.1002/prp2.70315

Image Credits: AI Generated

DOI: 10.1002/prp2.70315

Keywords: μ-opioid receptor, pharmacological chaperoning, naltrexone, naloxone, fentanyl, morphine, endoplasmic reticulum exit sites, Sec24D, opioid use disorder, receptor trafficking, S375 phosphorylation, inside-out pharmacology

But a stubborn handful of receptors has resisted every attempt at de-orphanization. TAS2R19, TAS2R42, TAS2R45, and TAS2R60 remain orphans, receptors with no known activating compounds, and their biological roles have therefore remained shrouded in uncertainty. At the same time, even among receptors classified as functional, genetic variation has produced variants labeled nonfunctional, sometimes on the basis of just one or a few amino acid substitutions. Two famous examples are TAS2R9 and TAS2R38. In TAS2R9, an alanine at position 187 yields a functional receptor, while a valine at the same position renders it unresponsive to known agonists such as the antibiotic ofloxacin. TAS2R38 is even more celebrated: its PAV variant makes people exquisitely sensitive to the bitter compounds phenylthiocarbamide and propylthiouracil, whereas the AVI variant is classed as nonfunctional and defines the classic taster-non-taster divide in human populations. Whether such variants are truly dead or have simply shifted their ligand preferences to unknown chemicals has been impossible to determine from sequence alone.

A new study by Praveen Kumar and Maik Behrens, published in Current Research in Food Science, tackles this puzzle from an unexpected angle. Instead of hunting for missing agonists, the researchers asked a more fundamental question: do these orphan and supposedly nonfunctional receptors even reach the cell surface, the location where a receptor must reside to detect compounds outside the cell? A receptor that fails to fold properly, or that gets stuck in the endoplasmic reticulum during biosynthesis, can never respond to any ligand, no matter how thorough the screening. Conversely, a receptor that traffics efficiently to the plasma membrane is structurally intact and remains a plausible candidate for future ligand discovery. The answer to this question provides a powerful clue about functionality that does not require knowing a single agonist.

To measure cell surface localization, the team employed a clever tagging strategy developed recently in their laboratory. Each receptor was engineered to carry an 11-amino-acid HiBiT sequence, a small peptide tag appended to the amino-terminal end of an sst3 export tag derived from the rat somatostatin receptor subtype 3, which is itself crucial for routing receptors to the plasma membrane. The HiBiT tag binds with high affinity to a complementary protein fragment called LgBiT, and together the two fragments generate luminescence. Because some of the commercial detection reagents are membrane-impermeable, they can only reach HiBiT tags exposed on the outside of living cells, allowing researchers to quantify exactly how much of each receptor sits at the cell surface. A second, lytic detection reagent breaks the cells open and reveals the total receptor population, permitting calculation of the fraction that successfully completed trafficking. The entire workflow runs on a fluorometric imaging plate reader, making it suitable for high-throughput analysis.

The first test cases were the taster and non-taster variants of TAS2R9 and TAS2R38. Functional assays in HEK293T-Gα16gust44 cells confirmed the expected behavior: the TAS2R38-PAV variant responded to propylthiouracil and the TAS2R9-187A variant responded to ofloxacin, while their non-taster counterparts remained silent. Importantly, adding the HiBiT tag did not abolish function, although the tagged TAS2R38 showed a slightly reduced response, a caveat the authors note openly. When the researchers then measured cell surface abundance using the luminescence assay, both functional and nonfunctional variants proved to be present at the plasma membrane. The non-taster TAS2R38-AVI variant reached the cell surface at a reduced fraction, about 6 percent of its total pool compared with 17 percent for the PAV variant, and the TAS2R9-187V variant showed only a modest reduction relative to its functional partner. Immunocytochemical staining of living, non-permeabilized cells with an anti-HiBiT antibody independently confirmed these surface-localization patterns.

These results carry significant implications for how scientists interpret receptor polymorphisms. For TAS2R9-187V, the data suggest that no gross defect in folding or routing explains its apparent nonfunctionality. Position 187 sits in the upper part of the fifth transmembrane domain, a region that could plausibly contribute to agonist binding. The authors therefore propose that rather than being a lost receptor, this variant may simply respond to a different, perhaps smaller, agonist that has not yet been tested. The bulkier valine residue could sterically reshape the ligand-binding pocket or restrict the conformational movements of the transmembrane helices needed for receptor activation. Similarly, for TAS2R38-AVI, the demonstration of structural integrity at the cell surface supports earlier speculation that this variant may have evolved altered ligand specificity, possibly responding to unknown compounds in the pulp of the Antidesma bunius fruit, which produces a peculiar bitter taste in individuals carrying the AVI haplotype.

The four orphan receptors yielded equally revealing results. All four could be detected at the cell surface by luminescence assays, but their trafficking efficiencies differed dramatically. TAS2R19 stood out as the star performer: 83 percent of its total receptor pool reached the plasma membrane, a proportion exceeding even that of TAS2R14, the human bitter receptor with the largest number of known agonists. TAS2R60 was by far the most abundantly produced receptor subtype, and although only 9 percent of it reached the surface, the absolute quantity there surpassed all TAS2Rs except TAS2R19. In sharp contrast, TAS2R42 and TAS2R45 showed negligible surface signals in immunocytochemical staining, with cell surface fractions of just 3 and 6 percent respectively. TAS2R42 is synthesized reasonably well but trafficked poorly, suggesting retention in the endoplasmic reticulum, while TAS2R45 appears to be produced at very low levels overall, raising the possibility that it may functionally represent an expressed pseudogene.

The contrasting profiles of the four orphans allow the authors to draw nuanced conclusions about why these receptors have resisted de-orphanization. For TAS2R19 and TAS2R60, biosynthesis and cell surface routing in heterologous cells clearly do not explain the absence of known agonists. Both receptors are closely related to already de-orphaned receptors in mice: the mouse receptor Tas2r135, an ortholog of TAS2R60, has 11 identified bitter agonists, and TAS2R19 is highly homologous to TAS2R20, which has 10 known agonists. Problems with coupling to the calcium signaling cascade used in the assay system also seem unlikely, given that far more distantly related receptors, including one from cartilaginous fish, have been successfully screened in the same cellular platform. The most probable explanation for these two receptors is simply that the right bitter compounds have not yet been tested, pointing toward unexplored chemical territory.

That territory, the authors argue, is vast and seriously under-sampled. Most bitter agonist discovery has focused on synthetic compounds and molecules from flowering plants, while bitter substances from animals, mushrooms and other fungi, prokaryotic organisms, and plants belonging to older lineages of the plant kingdom have barely been investigated. Recent work identifying bitter compounds from mushrooms, such as those isolated from the bracket fungus Amaropostia stiptica, illustrates the kind of neglected sources that could harbor activators for the remaining orphans. Closing this knowledge gap, the study suggests, will require intensified bioprospecting efforts guided by the growing recognition that bitter taste receptors do far more than guard the tongue. They are expressed in the gut, airways, and other tissues, where they influence hormone secretion, glucose homeostasis, and possibly innate defense, making every de-orphanized receptor a potential target for nutrition and medicine.

The HiBiT-based localization assay itself may prove to be the study’s most lasting contribution. By providing a rapid, quantitative, high-throughput readout of receptor biosynthetic integrity that requires no knowledge of agonists, the method offers a rational triage tool for the bitter taste receptor field. Receptors that traffic well, like TAS2R19 and TAS2R60, become priority targets for expanded ligand screening, while those with severe trafficking defects, like TAS2R42 and TAS2R45, may need engineered chaperones, modified expression systems, or tissue-specific organoid models to reveal their secrets. As the authors note, genetically engineered organoids derived from taste tissue or the intestine could eventually provide more natural cellular environments for such studies, overcoming limitations of immortalized cell lines that express numerous receptors endogenously. For now, the message is clear: four orphan receptors and two supposedly dead receptor variants are very much alive at the cell surface, waiting for the right molecule to wake them.

Subject of Research: Cell surface localization of orphan and nonfunctional human bitter taste receptors

Article Title: Cell surface localization of receptors considered nonfunctional and orphan bitter taste receptors

Article References: Kumar, P., & Behrens, M. (2026). Cell surface localization of receptors considered nonfunctional and orphan bitter taste receptors. Current Research in Food Science, 13, Article 101551. https://doi.org/10.1016/j.crfs.2026.101551

Image Credits: AI Generated

DOI: 10.1016/j.crfs.2026.101551

Keywords: bitter taste receptors, TAS2R, orphan receptors, HiBiT tag, cell surface localization, G protein-coupled receptors, TAS2R38, TAS2R9, de-orphanization, taste perception, receptor trafficking, food science